Minor gaps include no insurance acceptance and no BBB listing
The Medicare GLP-1 Bridge currently includes: Foundayo tablets ( NDCs: 0002-4178-31, 0002-4503-31, 0002-4794-31, 0002-4803-31, 0002-4839-31, 0002-4953-31) Wegovy injections (NDCs: 0169-4525-14, 0169-4505-14, 0169-4501-14, 0169-4517-14, 0169-4524-14, 0169-4572-14) Wegovy tablets (NDCs: 0169-4415-31, 0169-4404-31, 0169-4409-31, 0169-4425-31) Zepbound KwikPen (NDCs: 0002-3566-11, 0002-3555-11, 0002-3544-11, 0002-3533-11, 0002-3522-11, and 0002-3511-11) The following products are not included: Ozempic Mounjaro Compounded semaglutide Compounded tirzepatide Zepbound single-dose vials Zepbound single-dose pens Some of these medications may still be covered through regular Medicare Part D when prescribed for certain medical conditions
March 28, 2022
Outer thigh: The front outer quadrant of the thigh, roughly halfway between the knee and hip
But the finished product has not been tested in a rigorous clinical trial designed to measure GLP-1 levels, appetite changes, or weight outcomes against a placebo
Some insurance plans require step therapy (trying one medication before another), and some providers prefer starting with less potent options